Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Reversion from precore/core promoter mutants to wild-type hepatitis B virus during the course of lamivudine therapy.

Hepatology (Baltimore, Md.) - 1 Nov 2000

Cho S W, Hahm K B, Kim J H

Abstract excerpt

The effect of lamivudine administration on the evolution of precore/core promoter mutation is unknown. The aim of this study was to determine the changes of precore/core promoter sequences in chronic type B hepatitis patients treated with lamivudine. Serial sera were obtained from 11 patients before, at the beginning of, and during therapy. Serum samples were polymerase chain reaction-amplified, and nucleotide...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Gene Deletion
Share to Hepatitis B, Chronic
Share to Hepatitis B e Antigens

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepatitis B virus

Share to Lamivudine

Share to Promoter Regions, Genetic

Share to Reverse Transcriptase Inhibitors

Share to Viral Core Proteins

Source

Identifiers

PMID: 11050070
DOI: 10.1053/jhep.2000.19618

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Reversion from precore/core promoter mutants to wild-type hepatitis B virus during the course of lamivudine therapy.PMID 11050070Read ↗

Genetic heterogeneity of the precore and the core promoter region of genotype C hepatitis B virus during lamivudine therapy.Semantic proximity Read ↗

Evolution of hepatitis B virus precore/basal core promoter gene in HBeAg-positive chronic hepatitis B patients receiving lamivudine therapy.Semantic proximity Read ↗

Mutations of polymerase, precore and core promoter gene in hepatitis B virus during 5-year lamivudine therapy.Semantic proximity Read ↗

HBe antigen loss during lamivudine therapy is not caused by mutations in precore and core promoter genes in patients with chronic hepatitis B.Semantic proximity Read ↗

Comparison of sequence changes of precore and core promoter regions in HBeAg-positive chronic hepatitis B patients with and without HBeAg clearance in lamivudine therapy.Semantic proximity Read ↗

Clinical reactivation during lamivudine treatment correlates with mutations in the precore/core promoter and polymerase regions of hepatitis B virus in patients with anti-hepatitis B e-positive chronic hepatitis.Semantic proximity Read ↗

Evolution of precore/core promoter mutations in hepatitis B carriers with hepatitis B e antigen seroreversion.Semantic proximity Read ↗

Selection of precore mutants during lamivudine treatment in patients with chronic hepatitis B.Semantic proximity Read ↗

Changes in different regions of hepatitis B virus gene in hepatitis B 'e' antigen-negative patients with chronic hepatitis B: the effect of long-term lamivudine therapy.Semantic proximity Read ↗

Differences of YMDD mutational patterns, precore/core promoter mutations, serum HBV DNA levels in lamivudine-resistant hepatitis B genotypes B and C.Semantic proximity Read ↗

Different hepatitis B virus genotypes are associated with different mutations in the core promoter and precore regions during hepatitis B e antigen seroconversion.Semantic proximity Read ↗

Core promoter/pre-core mutations are associated with lamivudine-induced HBeAg loss in chronic hepatitis B with genotype C.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.